Company
Aqsens Health was founded in 2017 with the aim to improve the early detection of diseases using biological sampling and the E-TRF method. After a groundbreaking innovation in late 2020 to engineer the M13 phage with a specific color dye, the company started extensive R&D efforts to apply it to other phages and to detect diseases, which are hard to diagnose.
Today, the company has a strong patent portfolio around its method. Aqsens Health works together with world class science institutes and their clinical researchers in Finland, China, Ghana and the US, applying its biosensor method to revolutionize early detection of diseases.
Team
Our team consists of people with different backgrounds and skills, but all share a common goal – to improve healthcare, screening and diagnostics with innovative and scientifically-backed solutions.
-
Timo Teimonen
CEO & CO-FOUNDER
Business and strategy lead of the company.
timo.teimonen@aqbiotech.com
-
Janne Kulpakko
CHIEF SCIENCE OFFICER & CO-FOUNDER
Leading the company’s research work and new application development.
janne.kulpakko@aqbiotech.com
-
Elizabeth Cudjoe
SENIOR APPLICATION SCIENTIST
Phage-biosensor research and test development.
elizabeth.cudjoe@aqbiotech.com
-
Elinda Helin
APPLICATION SCIENTIST
Phage-biosensor research and test develpment
elinda.helin@aqbiotech.com
-
Zhao Zhao
PROJECT DIRECTOR
Management of the company's research and preclinical trials in China.
zhao.zhao@aqbiotech.com
Senior Clinical Advisors
-
Antti Rannikko
Professor of Urology at Helsinki University Hospital.
-
Maria Sundvall
MD Phd, Specialist Physician in Clinical Oncology at Turku University Hospital.
-
Tambet Teesalu
Professor of Nanomedicine and the head of the Laboratory of Precision and Nanomedicine at the University of Tartu.
-
Linda Eva Amoah
Associate Professor of Immunology at the Noguchi Memorial Institute for Medical Research.
-
Jouko Vepsäläinen
Professor of Chemistry at the University of Eastern Finland.